Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Gardiner hasn’t got a clue….
Needs to go ASAP
WET Cancer
Board cancer
“My take on what’s going on:”
That’s just my opinion we are all entitled to opinions you have enough
They need accounts signed off and No LD to fund hence car crash placing and dumping DX
The drug was approved 50+ years ago we are talking about a new delivery mechanism for an already approved drug that has nasty side effects.
Ava6000 eliminates these side effects and delivers more drug to the tumour and this is now proven.
My take on what’s going on:
Late last year Avacta was about to sign a LD with a major BP, hence the “dont worry about the funding “ comment.
But the results of the data coming in changed all this and the FDA are now in the driving seat with this trial knowing they want this to market ASAP.
For AS to state they have the Holy Grail after P1A data is the biggest hint to us all.
AS stated in Q&A we are in close talks with FDA and don’t want to jeopardise those talks on answering questions related to the trial.
P1B was suddenly changed to the 2W dose on FDA guidance.
( FDA don’t change your trial for more potent dosing then ask you to go back to original trial for P2)
Accelerated Approval is coming after 2W dose results.
That’s why LD was pulled and new terms are now being thrashed out for a BP partnership to get AVA6000 to market ASAP
It’s not the market that will light the fuse for Avacta’s SP rocket but the FDA
Call me a ramper if you want but just look at the evidence.
GLA
Reading blog below, I’m very very positive that AVA6000 receives FDA approval.
Just a Box ticking exercise for Avacta now.
https://www.science.org/content/blog-post/als-drug-fails-again
Tony joined Avacta from AHR, an international architecture and building consultancy practice, where he has held the role of Finance Director since 2011.
Not the experience you want doing billion pound deals…..
Winging it ….
Resign Gardiner you out of your depth and have cost thousands of LTH’s a massive drop in their net worth.
Everyone needs to hold to get back in the black, but we can’t let this man run the finance’s any longer with multi billion pound deals coming soon, use your votes at AGM to get rid.
Smith departed to the mountain bunker and stayed there for 40 days and nights in order to receive the 50p placing.
He was kept silent while the company has lost over half its value in that time because of the rules of his placement.
Pitch forks are out now and X (twitter) SH’s want him out.
I prefer Gardiner to go first with Smith moved sideways.
Yanks know about us….
Paula Takacs Foundation.
Since our inception in 2010, we have emerged one of the most active grassroots sarcoma foundations in the U.S.
https://paulatakacsfoundation.org/about-us/
https://paulatakacsfoundation.org/soft-tissue-sarcoma-pipeline-insight/
Little Avacta gets a mention.
* In September 2022, Avacta Group plc announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using the pre|CISION technology so that it is activated predominantly in the tumor with the aim of sparing healthy tissue from exposure and improving the safety, tolerability, and efficacy of the drug.
WET Cancer on here
jonathan his**** (born april 1974)[1] is a british hedge fund manager and founder of gsa capital, a london-based hedge fund.
shame on him shorting a company trying to save lives.
i wonder if the big c comes a knocking at his door or family members
Smith can’t be defended and needs to pull a bloody big rabbit out the bag to save his bacon.
Won’t do a deal with smaller companies so he gets a bigger deal later on.???
Just do a deal secure the cash and let BP decide what they are going to do about the smaller deals already done,If it’s the Holy Grail they will buy them out as well.
Just get LTH’s back in the black from the bloody car crash of a placing.
3 years of empty promises and kicking the can down the road.
LTH’ s need to see some action and answers from this board.
Ten Bob Tony won 7/1 at Newmarket today
Bloody hell 50p Tony Gardiner 😂😂
Pre|CISION+
Just came out the blue or have they working on this for a while, is this the reason Smith said “ funding don’t worry about that”
As soon as this patent is approved we could see some action in SP.
That haven’t commercialised Pre/Cision
But have now moved onto Pre/Cision +
I have a feeling there is a Major announcement coming very soon…
The Avacta pre|CISION+ platform is based on the peptide drug conjugate delivery model which is then conjugated to a biologic protein moiety such as the Fc region of an antibody or AffimerXT® to significantly extend the half-life and optimise the pharmacokinetics of the peptide drug conjugate.
Significant extension of the half-life of the pre|CISIONTM warhead will benefit certain warheads that target tumours differently from traditional cytotoxics. Examples of such pre|CISION+ warheads include cancer pathway targeted therapies or immune modulators where more consistent and concentrated delivery to the TME is optimal.
WET Cancer go away
Has any company ever presented chemo results to the FDA with so little side effects.
Would it not be ethical that the FDA approve as quick as possible.
These results must set a precedent on the grounds of safety even if showing just the efficacy shown so far.
Why would LG Chem,Daewoong and Eli Lilly
All pay $180m LG Chem,
Daewoong give 25% of Affxell,
Eli Lilly pay licence fee on Point Bio deal.
When any of them only has to offer a cheeky T/O price now to test PI’s patience.
II’s still the minority in this company.
At £180m MCap, Smith & Gardiner and the board have put Avacta on a very dangerous position.
LG Chem
This multi-target therapeutics development agreement provides for upfront and near-term milestone payments, plus longer-term clinical development milestones totalling $180million.
Daewoong
The second milestone will result in an increase in Avacta's shareholding in AffyXell, which currently stands at 19%. The exact shareholding will be determined, as with the first milestone payment which was achieved in April 2022, following a formal valuation of AffyXell.
Our presentation at #AACR24 today - well received with many intriguing conversations.
Grateful and humbled by our lead author Prof @udai_banerji who did not stop speaking for 3.5 hours. Udai - much appreciated
#PeptidesCreateHope
#LetsDoThis